Roche Sequencing Solutions, Inc. entered into an agreement to acquire Global license of double-stranded DNA from Codexis, Inc. on February 26, 2024. Under the terms of the deal, Codexis will receive upfront and technical milestone payments.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.135 USD | +8.10% |
|
+13.17% | +4.26% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.26% | 205M | |
+25.50% | 52.73B | |
+37.49% | 39B | |
-9.14% | 38.52B | |
+28.00% | 30.38B | |
-12.26% | 26.39B | |
+10.46% | 26.08B | |
+45.00% | 14.15B | |
+32.34% | 12.6B | |
-6.14% | 11.51B |
- Stock Market
- Equities
- CDXS Stock
- News Codexis, Inc.
- Roche Sequencing Solutions, Inc. entered into an agreement to acquire Global license of double-stranded DNA from Codexis, Inc.